Literature DB >> 24044015

Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.

Soonyoung Park1, Jooyoung Lee, Sang Yeub Lee, Jang-Whan Bae, Kyung-Kuk Hwang, Dong-Woon Kim, Myeong-Chan Cho, Sang Min Kim.   

Abstract

Glycoprotein IIb/IIIa antagonists are well established for their effectiveness in improving clinical outcomes in acute coronary syndrome patients undergoing percutaneous coronary intervention. Acute profound thrombocytopenia is a rare complication of abciximab. We present a case which was managed successfully for the rare complication of acute profound thrombocytopenia after using abciximab and an intra-aortic balloon pump for the treatment of a no-reflow phenomenon and consecutive cardiogenic shock during primary percutaneous coronary intervention.

Entities:  

Keywords:  Abciximab; No-reflow phenomenon; Thrombocytopenia

Year:  2013        PMID： 24044015      PMCID： PMC3772301          DOI： 10.4070/kcj.2013.43.8.557

Source DB:  PubMed          Journal:  Korean Circ J        ISSN： 1738-5520            Impact factor:   3.243


  11 in total

Review 1.  Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature.

Authors:  S N Makoni
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

Review 2.  Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory.

Authors:  Lloyd W Klein; Morton J Kern; Peter Berger; Timothy Sanborn; Peter Block; Joseph Babb; Carl Tommaso; John McB Hodgson; Ted Feldman
Journal:  Catheter Cardiovasc Interv       Date:  2003-10       Impact factor: 2.692

Review 3.  Heparin-induced thrombocytopenia: pathogenesis and management.

Authors:  Theodore E Warkentin
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

4.  Major bleeding and severe thrombocytopenia after combined heparin and abciximab-c7E3 Fab therapy.

Authors:  L G Y Claeys; W Berg
Journal:  Eur J Vasc Endovasc Surg       Date:  2003-01       Impact factor: 7.069

Review 5.  Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy.

Authors:  B S Coller
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

6.  Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Authors:  A M Lincoff; D B Mark; J E Tcheng; R M Califf; M V Bala; K M Anderson; L Davidson-Ray; J D Knight; C F Cabot; E J Topol
Journal:  Circulation       Date:  2000-12-12       Impact factor: 29.690

7.  Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.

Authors:  Piera Angelica Merlini; Marco Rossi; Alberto Menozzi; Silvia Buratti; Danielle M Brennan; David J Moliterno; Eric J Topol; Diego Ardissino
Journal:  Circulation       Date:  2004-04-26       Impact factor: 29.690

8.  Features and outcome of no-reflow after percutaneous coronary intervention.

Authors:  K M Abbo; M Dooris; S Glazier; W W O'Neill; D Byrd; C L Grines; R D Safian
Journal:  Am J Cardiol       Date:  1995-04-15       Impact factor: 2.778

9.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-07       Impact factor: 91.245

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321
View more
  1 in total

1.  Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention.

Authors:  Todd Golden; Sehem Ghazala; Rita Wadeea; Shilpa Junna
Journal:  BMJ Case Rep       Date:  2017-07-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.